JP2012523440A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2012523440A5 JP2012523440A5 JP2012505103A JP2012505103A JP2012523440A5 JP 2012523440 A5 JP2012523440 A5 JP 2012523440A5 JP 2012505103 A JP2012505103 A JP 2012505103A JP 2012505103 A JP2012505103 A JP 2012505103A JP 2012523440 A5 JP2012523440 A5 JP 2012523440A5
- Authority
- JP
- Japan
- Prior art keywords
- indol
- bromo
- chloro
- hydroxypropyl
- cycloheptylacetamide
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- -1 piperidino, morpholino, pyrrolidino, 5H-tetrazolyl propyl Chemical group 0.000 claims 19
- 150000001875 compounds Chemical class 0.000 claims 10
- 239000008194 pharmaceutical composition Substances 0.000 claims 8
- 229910052736 halogen Inorganic materials 0.000 claims 3
- 150000002367 halogens Chemical class 0.000 claims 3
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 claims 2
- 208000019022 Mood disease Diseases 0.000 claims 2
- 150000001602 bicycloalkyls Chemical group 0.000 claims 2
- 229910052794 bromium Inorganic materials 0.000 claims 2
- 229910052801 chlorine Inorganic materials 0.000 claims 2
- 125000004093 cyano group Chemical group *C#N 0.000 claims 2
- 230000003412 degenerative effect Effects 0.000 claims 2
- 208000037765 diseases and disorders Diseases 0.000 claims 2
- 229910052731 fluorine Inorganic materials 0.000 claims 2
- 229910052739 hydrogen Inorganic materials 0.000 claims 2
- 239000001257 hydrogen Substances 0.000 claims 2
- 230000004054 inflammatory process Effects 0.000 claims 2
- 229910052740 iodine Inorganic materials 0.000 claims 2
- 230000001404 mediated effect Effects 0.000 claims 2
- 208000004296 neuralgia Diseases 0.000 claims 2
- 208000015122 neurodegenerative disease Diseases 0.000 claims 2
- 208000021722 neuropathic pain Diseases 0.000 claims 2
- 208000017194 Affective disease Diseases 0.000 claims 1
- 208000024827 Alzheimer disease Diseases 0.000 claims 1
- 208000019901 Anxiety disease Diseases 0.000 claims 1
- 208000020925 Bipolar disease Diseases 0.000 claims 1
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 claims 1
- 208000006545 Chronic Obstructive Pulmonary Disease Diseases 0.000 claims 1
- 208000010412 Glaucoma Diseases 0.000 claims 1
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims 1
- 229910017711 NHRa Inorganic materials 0.000 claims 1
- 208000036110 Neuroinflammatory disease Diseases 0.000 claims 1
- 208000001132 Osteoporosis Diseases 0.000 claims 1
- 208000002193 Pain Diseases 0.000 claims 1
- 208000018737 Parkinson disease Diseases 0.000 claims 1
- 206010046851 Uveitis Diseases 0.000 claims 1
- 206010064930 age-related macular degeneration Diseases 0.000 claims 1
- 125000000217 alkyl group Chemical group 0.000 claims 1
- 206010002026 amyotrophic lateral sclerosis Diseases 0.000 claims 1
- 230000036506 anxiety Effects 0.000 claims 1
- 229910052799 carbon Inorganic materials 0.000 claims 1
- 125000000582 cycloheptyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 claims 1
- 125000006622 cycloheptylmethyl group Chemical group 0.000 claims 1
- 125000000113 cyclohexyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 claims 1
- 125000004210 cyclohexylmethyl group Chemical group [H]C([H])(*)C1([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C1([H])[H] 0.000 claims 1
- 125000001511 cyclopentyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 claims 1
- 125000004851 cyclopentylmethyl group Chemical group C1(CCCC1)C* 0.000 claims 1
- 150000002431 hydrogen Chemical class 0.000 claims 1
- 208000002780 macular degeneration Diseases 0.000 claims 1
- 125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 claims 1
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims 1
- 201000006417 multiple sclerosis Diseases 0.000 claims 1
- SFQWCPUWXNABQE-UHFFFAOYSA-N n-(4-bromo-1-methylindol-3-yl)-2-cycloheptylacetamide Chemical compound C12=C(Br)C=CC=C2N(C)C=C1NC(=O)CC1CCCCCC1 SFQWCPUWXNABQE-UHFFFAOYSA-N 0.000 claims 1
- DLTVKHKUMNDDAH-UHFFFAOYSA-N n-(4-bromo-1-methylindol-3-yl)-2-cyclohexylacetamide Chemical compound C12=C(Br)C=CC=C2N(C)C=C1NC(=O)CC1CCCCC1 DLTVKHKUMNDDAH-UHFFFAOYSA-N 0.000 claims 1
- MYGYHZJROGQMBC-UHFFFAOYSA-N n-(4-bromo-1-methylindol-3-yl)-3-cycloheptylpropanamide Chemical compound C12=C(Br)C=CC=C2N(C)C=C1NC(=O)CCC1CCCCCC1 MYGYHZJROGQMBC-UHFFFAOYSA-N 0.000 claims 1
- CMEKOLJCXWMDIX-UHFFFAOYSA-N n-(4-bromo-1-methylindol-3-yl)-3-cyclohexylpropanamide Chemical compound C12=C(Br)C=CC=C2N(C)C=C1NC(=O)CCC1CCCCC1 CMEKOLJCXWMDIX-UHFFFAOYSA-N 0.000 claims 1
- ISSAMEPSMOIHJK-UHFFFAOYSA-N n-(4-chloro-1-methylindol-3-yl)-2-cycloheptylacetamide Chemical compound C12=C(Cl)C=CC=C2N(C)C=C1NC(=O)CC1CCCCCC1 ISSAMEPSMOIHJK-UHFFFAOYSA-N 0.000 claims 1
- OGWPQDTZTLCWMN-UHFFFAOYSA-N n-(4-chloro-1-methylindol-3-yl)-2-cyclohexylacetamide Chemical compound C12=C(Cl)C=CC=C2N(C)C=C1NC(=O)CC1CCCCC1 OGWPQDTZTLCWMN-UHFFFAOYSA-N 0.000 claims 1
- CRTHKMLUELCZJE-UHFFFAOYSA-N n-(4-chloro-1-methylindol-3-yl)-3-cycloheptylpropanamide Chemical compound C12=C(Cl)C=CC=C2N(C)C=C1NC(=O)CCC1CCCCCC1 CRTHKMLUELCZJE-UHFFFAOYSA-N 0.000 claims 1
- OABNVPUYZRLOCL-UHFFFAOYSA-N n-(4-chloro-1-methylindol-3-yl)-3-cyclohexylpropanamide Chemical compound C12=C(Cl)C=CC=C2N(C)C=C1NC(=O)CCC1CCCCC1 OABNVPUYZRLOCL-UHFFFAOYSA-N 0.000 claims 1
- HEMQGUMFWNJOPJ-UHFFFAOYSA-N n-[1-(3-amino-2-hydroxypropyl)-4-bromoindol-3-yl]-2-cycloheptylacetamide Chemical compound C12=C(Br)C=CC=C2N(CC(O)CN)C=C1NC(=O)CC1CCCCCC1 HEMQGUMFWNJOPJ-UHFFFAOYSA-N 0.000 claims 1
- YEKWPKSJTPUULO-UHFFFAOYSA-N n-[1-(3-amino-2-hydroxypropyl)-4-bromoindol-3-yl]-2-cyclohexylacetamide Chemical compound C12=C(Br)C=CC=C2N(CC(O)CN)C=C1NC(=O)CC1CCCCC1 YEKWPKSJTPUULO-UHFFFAOYSA-N 0.000 claims 1
- PDEOYPPQJJUNGU-UHFFFAOYSA-N n-[1-(3-amino-2-hydroxypropyl)-4-bromoindol-3-yl]-3-cycloheptylpropanamide Chemical compound C12=C(Br)C=CC=C2N(CC(O)CN)C=C1NC(=O)CCC1CCCCCC1 PDEOYPPQJJUNGU-UHFFFAOYSA-N 0.000 claims 1
- MOTOJNXOWKVYCB-UHFFFAOYSA-N n-[1-(3-amino-2-hydroxypropyl)-4-bromoindol-3-yl]-3-cyclohexylpropanamide Chemical compound C12=C(Br)C=CC=C2N(CC(O)CN)C=C1NC(=O)CCC1CCCCC1 MOTOJNXOWKVYCB-UHFFFAOYSA-N 0.000 claims 1
- ZRSPQUBTFYDJPH-UHFFFAOYSA-N n-[1-(3-amino-2-hydroxypropyl)-4-chloroindol-3-yl]-2-cyclohexylacetamide Chemical compound C12=C(Cl)C=CC=C2N(CC(O)CN)C=C1NC(=O)CC1CCCCC1 ZRSPQUBTFYDJPH-UHFFFAOYSA-N 0.000 claims 1
- RLSLAFGZBRDMCQ-UHFFFAOYSA-N n-[1-(3-amino-2-hydroxypropyl)-4-chloroindol-3-yl]-3-cycloheptylpropanamide Chemical compound C12=C(Cl)C=CC=C2N(CC(O)CN)C=C1NC(=O)CCC1CCCCCC1 RLSLAFGZBRDMCQ-UHFFFAOYSA-N 0.000 claims 1
- VKUZEUVMCUPMPK-UHFFFAOYSA-N n-[1-(3-amino-2-hydroxypropyl)-4-chloroindol-3-yl]-3-cyclohexylpropanamide Chemical compound C12=C(Cl)C=CC=C2N(CC(O)CN)C=C1NC(=O)CCC1CCCCC1 VKUZEUVMCUPMPK-UHFFFAOYSA-N 0.000 claims 1
- CHOANFGJVZEOFH-UHFFFAOYSA-N n-[4-bromo-1-(1,3-dihydroxypropan-2-yl)indol-3-yl]-2-cycloheptylacetamide Chemical compound C12=C(Br)C=CC=C2N(C(CO)CO)C=C1NC(=O)CC1CCCCCC1 CHOANFGJVZEOFH-UHFFFAOYSA-N 0.000 claims 1
- OPNGEBMRRPPJHP-UHFFFAOYSA-N n-[4-bromo-1-(1,3-dihydroxypropan-2-yl)indol-3-yl]-2-cyclohexylacetamide Chemical compound C12=C(Br)C=CC=C2N(C(CO)CO)C=C1NC(=O)CC1CCCCC1 OPNGEBMRRPPJHP-UHFFFAOYSA-N 0.000 claims 1
- MBXYMPOSQUTDKU-UHFFFAOYSA-N n-[4-bromo-1-(1,3-dihydroxypropan-2-yl)indol-3-yl]-3-cycloheptylpropanamide Chemical compound C12=C(Br)C=CC=C2N(C(CO)CO)C=C1NC(=O)CCC1CCCCCC1 MBXYMPOSQUTDKU-UHFFFAOYSA-N 0.000 claims 1
- LZLCSZIYRMQUMS-UHFFFAOYSA-N n-[4-bromo-1-(1,3-dihydroxypropan-2-yl)indol-3-yl]-3-cyclohexylpropanamide Chemical compound C12=C(Br)C=CC=C2N(C(CO)CO)C=C1NC(=O)CCC1CCCCC1 LZLCSZIYRMQUMS-UHFFFAOYSA-N 0.000 claims 1
- SVVOELFVCLNEGG-UHFFFAOYSA-N n-[4-bromo-1-(2-hydroxyethyl)indol-3-yl]-2-cycloheptylacetamide Chemical compound C12=C(Br)C=CC=C2N(CCO)C=C1NC(=O)CC1CCCCCC1 SVVOELFVCLNEGG-UHFFFAOYSA-N 0.000 claims 1
- YROYXIDRTRDMTE-UHFFFAOYSA-N n-[4-bromo-1-(2-hydroxyethyl)indol-3-yl]-2-cyclohexylacetamide Chemical compound C12=C(Br)C=CC=C2N(CCO)C=C1NC(=O)CC1CCCCC1 YROYXIDRTRDMTE-UHFFFAOYSA-N 0.000 claims 1
- YAQUKGTUOXFJJQ-UHFFFAOYSA-N n-[4-bromo-1-(2-hydroxyethyl)pyrrolo[2,3-b]pyridin-3-yl]-2-cycloheptylacetamide Chemical compound C12=C(Br)C=CN=C2N(CCO)C=C1NC(=O)CC1CCCCCC1 YAQUKGTUOXFJJQ-UHFFFAOYSA-N 0.000 claims 1
- KNOJYDFTQTURPA-UHFFFAOYSA-N n-[4-bromo-1-(2-hydroxyethyl)pyrrolo[2,3-b]pyridin-3-yl]-2-cyclohexylacetamide Chemical compound C12=C(Br)C=CN=C2N(CCO)C=C1NC(=O)CC1CCCCC1 KNOJYDFTQTURPA-UHFFFAOYSA-N 0.000 claims 1
- WDSFRYRDDZNRFI-UHFFFAOYSA-N n-[4-bromo-1-(2-hydroxyethyl)pyrrolo[2,3-b]pyridin-3-yl]-3-cyclohexylpropanamide Chemical compound C12=C(Br)C=CN=C2N(CCO)C=C1NC(=O)CCC1CCCCC1 WDSFRYRDDZNRFI-UHFFFAOYSA-N 0.000 claims 1
- OFAVBMQFOMTSNS-UHFFFAOYSA-N n-[4-bromo-1-(2-hydroxypropyl)indol-3-yl]-2-cycloheptylacetamide Chemical compound C12=C(Br)C=CC=C2N(CC(O)C)C=C1NC(=O)CC1CCCCCC1 OFAVBMQFOMTSNS-UHFFFAOYSA-N 0.000 claims 1
- IUYJIHUNZJXWLV-UHFFFAOYSA-N n-[4-bromo-1-(2-hydroxypropyl)indol-3-yl]-2-cyclohexylacetamide Chemical compound C12=C(Br)C=CC=C2N(CC(O)C)C=C1NC(=O)CC1CCCCC1 IUYJIHUNZJXWLV-UHFFFAOYSA-N 0.000 claims 1
- DGMCKLKRZYXGKX-UHFFFAOYSA-N n-[4-bromo-1-(2-hydroxypropyl)indol-3-yl]-3-cycloheptylpropanamide Chemical compound C12=C(Br)C=CC=C2N(CC(O)C)C=C1NC(=O)CCC1CCCCCC1 DGMCKLKRZYXGKX-UHFFFAOYSA-N 0.000 claims 1
- YXCLCFKUJGINNC-UHFFFAOYSA-N n-[4-bromo-1-(2-hydroxypropyl)indol-3-yl]-3-cyclohexylpropanamide Chemical compound C12=C(Br)C=CC=C2N(CC(O)C)C=C1NC(=O)CCC1CCCCC1 YXCLCFKUJGINNC-UHFFFAOYSA-N 0.000 claims 1
- YHSFNEREALZUKL-UHFFFAOYSA-N n-[4-bromo-1-(2-hydroxypropyl)pyrrolo[2,3-b]pyridin-3-yl]-2-cycloheptylacetamide Chemical compound C12=C(Br)C=CN=C2N(CC(O)C)C=C1NC(=O)CC1CCCCCC1 YHSFNEREALZUKL-UHFFFAOYSA-N 0.000 claims 1
- AADNCGJNLRDGMG-UHFFFAOYSA-N n-[4-bromo-1-(hydroxymethyl)indol-3-yl]-3-cycloheptylpropanamide Chemical compound C12=C(Br)C=CC=C2N(CO)C=C1NC(=O)CCC1CCCCCC1 AADNCGJNLRDGMG-UHFFFAOYSA-N 0.000 claims 1
- JNGLUTOXXKAMJN-UHFFFAOYSA-N n-[4-bromo-1-(hydroxymethyl)indol-3-yl]-3-cyclohexylpropanamide Chemical compound C12=C(Br)C=CC=C2N(CO)C=C1NC(=O)CCC1CCCCC1 JNGLUTOXXKAMJN-UHFFFAOYSA-N 0.000 claims 1
- RURAJWCFGSAIHX-UHFFFAOYSA-N n-[4-bromo-1-[2-hydroxy-3-(methylamino)propyl]indol-3-yl]-2-cycloheptylacetamide Chemical compound C12=C(Br)C=CC=C2N(CC(O)CNC)C=C1NC(=O)CC1CCCCCC1 RURAJWCFGSAIHX-UHFFFAOYSA-N 0.000 claims 1
- JXIOLPVODQMGNN-UHFFFAOYSA-N n-[4-bromo-1-[2-hydroxy-3-(methylamino)propyl]indol-3-yl]-2-cyclohexylacetamide Chemical compound C12=C(Br)C=CC=C2N(CC(O)CNC)C=C1NC(=O)CC1CCCCC1 JXIOLPVODQMGNN-UHFFFAOYSA-N 0.000 claims 1
- IMPXQWGQCWTHPG-UHFFFAOYSA-N n-[4-chloro-1-(1,3-dihydroxypropan-2-yl)indol-3-yl]-2-cycloheptylacetamide Chemical compound C12=C(Cl)C=CC=C2N(C(CO)CO)C=C1NC(=O)CC1CCCCCC1 IMPXQWGQCWTHPG-UHFFFAOYSA-N 0.000 claims 1
- HIIVSNPXBZCNEN-UHFFFAOYSA-N n-[4-chloro-1-(1,3-dihydroxypropan-2-yl)indol-3-yl]-2-cyclohexylacetamide Chemical compound C12=C(Cl)C=CC=C2N(C(CO)CO)C=C1NC(=O)CC1CCCCC1 HIIVSNPXBZCNEN-UHFFFAOYSA-N 0.000 claims 1
- DVTXIRRZDXMDPE-UHFFFAOYSA-N n-[4-chloro-1-(1,3-dihydroxypropan-2-yl)indol-3-yl]-3-cycloheptylpropanamide Chemical compound C12=C(Cl)C=CC=C2N(C(CO)CO)C=C1NC(=O)CCC1CCCCCC1 DVTXIRRZDXMDPE-UHFFFAOYSA-N 0.000 claims 1
- CVXARHQUPAZUEY-UHFFFAOYSA-N n-[4-chloro-1-(1,3-dihydroxypropan-2-yl)indol-3-yl]-3-cyclohexylpropanamide Chemical compound C12=C(Cl)C=CC=C2N(C(CO)CO)C=C1NC(=O)CCC1CCCCC1 CVXARHQUPAZUEY-UHFFFAOYSA-N 0.000 claims 1
- NDWPJXLFSZNCQI-UHFFFAOYSA-N n-[4-chloro-1-(2-hydroxyethyl)indol-3-yl]-2-cycloheptylacetamide Chemical compound C12=C(Cl)C=CC=C2N(CCO)C=C1NC(=O)CC1CCCCCC1 NDWPJXLFSZNCQI-UHFFFAOYSA-N 0.000 claims 1
- KZCSGGNZYJERJX-UHFFFAOYSA-N n-[4-chloro-1-(2-hydroxyethyl)indol-3-yl]-2-cyclohexylacetamide Chemical compound C12=C(Cl)C=CC=C2N(CCO)C=C1NC(=O)CC1CCCCC1 KZCSGGNZYJERJX-UHFFFAOYSA-N 0.000 claims 1
- RYSUBWBWGLTRPX-UHFFFAOYSA-N n-[4-chloro-1-(2-hydroxyethyl)pyrrolo[2,3-b]pyridin-3-yl]-2-cycloheptylacetamide Chemical compound C12=C(Cl)C=CN=C2N(CCO)C=C1NC(=O)CC1CCCCCC1 RYSUBWBWGLTRPX-UHFFFAOYSA-N 0.000 claims 1
- MMERRSUZVKPFDU-UHFFFAOYSA-N n-[4-chloro-1-(2-hydroxyethyl)pyrrolo[2,3-b]pyridin-3-yl]-2-cyclohexylacetamide Chemical compound C12=C(Cl)C=CN=C2N(CCO)C=C1NC(=O)CC1CCCCC1 MMERRSUZVKPFDU-UHFFFAOYSA-N 0.000 claims 1
- WDGOQXSORIOXEP-UHFFFAOYSA-N n-[4-chloro-1-(2-hydroxyethyl)pyrrolo[2,3-b]pyridin-3-yl]-3-cyclohexylpropanamide Chemical compound C12=C(Cl)C=CN=C2N(CCO)C=C1NC(=O)CCC1CCCCC1 WDGOQXSORIOXEP-UHFFFAOYSA-N 0.000 claims 1
- ZSZGKSFMXPUDOB-UHFFFAOYSA-N n-[4-chloro-1-(2-hydroxypropyl)indol-3-yl]-2-cycloheptylacetamide Chemical compound C12=C(Cl)C=CC=C2N(CC(O)C)C=C1NC(=O)CC1CCCCCC1 ZSZGKSFMXPUDOB-UHFFFAOYSA-N 0.000 claims 1
- OSSYXOZWCDPUDL-UHFFFAOYSA-N n-[4-chloro-1-(2-hydroxypropyl)indol-3-yl]-2-cyclohexylacetamide Chemical compound C12=C(Cl)C=CC=C2N(CC(O)C)C=C1NC(=O)CC1CCCCC1 OSSYXOZWCDPUDL-UHFFFAOYSA-N 0.000 claims 1
- SFONSAAWBCIDER-UHFFFAOYSA-N n-[4-chloro-1-(2-hydroxypropyl)indol-3-yl]-3-cycloheptylpropanamide Chemical compound C12=C(Cl)C=CC=C2N(CC(O)C)C=C1NC(=O)CCC1CCCCCC1 SFONSAAWBCIDER-UHFFFAOYSA-N 0.000 claims 1
- RSXJYBYZMWKNAB-UHFFFAOYSA-N n-[4-chloro-1-(2-hydroxypropyl)indol-3-yl]-3-cyclohexylpropanamide Chemical compound C12=C(Cl)C=CC=C2N(CC(O)C)C=C1NC(=O)CCC1CCCCC1 RSXJYBYZMWKNAB-UHFFFAOYSA-N 0.000 claims 1
- NYDOQLJTXSWCJK-UHFFFAOYSA-N n-[4-chloro-1-(2-hydroxypropyl)pyrrolo[2,3-b]pyridin-3-yl]-2-cycloheptylacetamide Chemical compound C12=C(Cl)C=CN=C2N(CC(O)C)C=C1NC(=O)CC1CCCCCC1 NYDOQLJTXSWCJK-UHFFFAOYSA-N 0.000 claims 1
- XMTIJJMTSVLVBM-UHFFFAOYSA-N n-[4-chloro-1-(hydroxymethyl)indol-3-yl]-3-cycloheptylpropanamide Chemical compound C12=C(Cl)C=CC=C2N(CO)C=C1NC(=O)CCC1CCCCCC1 XMTIJJMTSVLVBM-UHFFFAOYSA-N 0.000 claims 1
- CPACRRVJKRXGDW-UHFFFAOYSA-N n-[4-chloro-1-(hydroxymethyl)indol-3-yl]-3-cyclohexylpropanamide Chemical compound C12=C(Cl)C=CC=C2N(CO)C=C1NC(=O)CCC1CCCCC1 CPACRRVJKRXGDW-UHFFFAOYSA-N 0.000 claims 1
- YUPOWXNTYRBUEA-UHFFFAOYSA-N n-[4-chloro-1-[2-hydroxy-3-(methylamino)propyl]indol-3-yl]-2-cycloheptylacetamide Chemical compound C12=C(Cl)C=CC=C2N(CC(O)CNC)C=C1NC(=O)CC1CCCCCC1 YUPOWXNTYRBUEA-UHFFFAOYSA-N 0.000 claims 1
- IJLCBKMUNKBIDV-UHFFFAOYSA-N n-[4-chloro-1-[2-hydroxy-3-(methylamino)propyl]indol-3-yl]-2-cyclohexylacetamide Chemical compound C12=C(Cl)C=CC=C2N(CC(O)CNC)C=C1NC(=O)CC1CCCCC1 IJLCBKMUNKBIDV-UHFFFAOYSA-N 0.000 claims 1
- 230000004770 neurodegeneration Effects 0.000 claims 1
- 230000003959 neuroinflammation Effects 0.000 claims 1
- 229910052757 nitrogen Inorganic materials 0.000 claims 1
- 230000036407 pain Effects 0.000 claims 1
- 206010039073 rheumatoid arthritis Diseases 0.000 claims 1
- 150000003839 salts Chemical class 0.000 claims 1
- 201000000980 schizophrenia Diseases 0.000 claims 1
- 239000012453 solvate Substances 0.000 claims 1
- 125000001424 substituent group Chemical group 0.000 claims 1
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 claims 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP09005324 | 2009-04-14 | ||
| EP09005324.0 | 2009-04-14 | ||
| PCT/EP2010/053097 WO2010118921A1 (en) | 2009-04-14 | 2010-03-11 | Novel p2x7r antagonists and their use |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2012523440A JP2012523440A (ja) | 2012-10-04 |
| JP2012523440A5 true JP2012523440A5 (enExample) | 2013-04-25 |
Family
ID=42167925
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2012505103A Pending JP2012523440A (ja) | 2009-04-14 | 2010-03-11 | 新規ｐ２ｘ７ｒ拮抗薬およびその使用 |
Country Status (23)
| Country | Link |
|---|---|
| US (2) | US7919503B2 (enExample) |
| EP (1) | EP2243772B1 (enExample) |
| JP (1) | JP2012523440A (enExample) |
| KR (1) | KR20120006547A (enExample) |
| CN (1) | CN102395562A (enExample) |
| AT (1) | ATE541832T1 (enExample) |
| AU (1) | AU2010237302A1 (enExample) |
| BR (1) | BRPI1014902A2 (enExample) |
| CA (1) | CA2758474A1 (enExample) |
| CY (1) | CY1112758T1 (enExample) |
| DK (1) | DK2243772T3 (enExample) |
| EA (1) | EA201101479A1 (enExample) |
| ES (1) | ES2380908T3 (enExample) |
| HR (1) | HRP20120271T1 (enExample) |
| IL (1) | IL215444A0 (enExample) |
| MX (1) | MX2011010810A (enExample) |
| PL (1) | PL2243772T3 (enExample) |
| PT (1) | PT2243772E (enExample) |
| SG (1) | SG175232A1 (enExample) |
| SI (1) | SI2243772T1 (enExample) |
| SM (1) | SMT201200017B (enExample) |
| WO (1) | WO2010118921A1 (enExample) |
| ZA (1) | ZA201108305B (enExample) |
Families Citing this family (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US8815892B2 (en) | 2008-03-25 | 2014-08-26 | Affectis Pharmaceuticals Ag | P2X7R antagonists and their use |
| US8232290B2 (en) * | 2008-03-25 | 2012-07-31 | Affectis Pharmaceuticals Ag | P2X7R antagonists and their use |
| AU2011252351A1 (en) * | 2010-05-14 | 2012-10-11 | Affectis Pharmaceuticals Ag | Novel methods for the preparation of P2X7R antagonists |
| WO2012110190A1 (en) | 2011-02-17 | 2012-08-23 | Affectis Pharmaceuticals Ag | Novel p2x7r antagonists and their use |
| EP2701719A4 (en) * | 2011-04-28 | 2015-04-22 | Claire Mitchell | METHOD FOR TREATING MACULAR OBGENATION BY MODULATION OF P2Y12 OR P2X7 RECEPTORS |
| WO2012163792A1 (en) | 2011-05-27 | 2012-12-06 | Affectis Pharmaceuticals Ag | Novel p2x7r antagonists and their use |
| WO2012163456A1 (en) | 2011-05-27 | 2012-12-06 | Affectis Pharmaceuticals Ag | Novel p2x7r antagonists and their use |
| KR101995088B1 (ko) * | 2011-07-22 | 2019-07-02 | 이도르시아 파마슈티컬스 리미티드 | Ｐ2ｘ7 수용체 길항제로서의 헤테로시클릭 아미드 유도체 |
| US20140322193A1 (en) * | 2011-12-02 | 2014-10-30 | Michael Kaleko | Therapies for Disorders of the Cornea and Conjunctiva |
| MX336247B (es) | 2012-01-20 | 2016-01-13 | Actelion Pharmaceuticals Ltd | Derivados de amida heterociclicos como antagonistas del receptor p2x7. |
| US9718774B2 (en) | 2012-12-12 | 2017-08-01 | Idorsia Pharmaceuticals Ltd | Indole carboxamide derivatives as P2X7 receptor antagonist |
| AR094053A1 (es) | 2012-12-18 | 2015-07-08 | Actelion Pharmaceuticals Ltd | Derivados de indol carboxamida como antagonistas del receptor p2x₇ |
| EP2956135B1 (en) | 2013-01-22 | 2016-11-16 | Actelion Pharmaceuticals Ltd. | Heterocyclic amide derivatives as p2x7 receptor antagonists |
| KR102220847B1 (ko) | 2013-01-22 | 2021-02-26 | 이도르시아 파마슈티컬스 리미티드 | Ｐ2ｘ7 수용체 길항제로서의 헤테로시클릭 아미드 유도체 |
| WO2014182601A1 (en) | 2013-05-08 | 2014-11-13 | Children's Medical Center Corporation | A method of preventing and treating type 1 diabetes, allograft rejection and lung fibrosis (by targeting the atp/p2x7r axis) |
| WO2020150417A2 (en) * | 2019-01-17 | 2020-07-23 | Ifm Due, Inc. | Compounds and compositions for treating conditions associated with sting activity |
| TW202317087A (zh) | 2021-08-10 | 2023-05-01 | 美商Ｉｆｍ Ｄｕｅ有限公司 | 用於治療與sting活性相關病況之化合物及組合物 |
Family Cites Families (81)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3705175A (en) * | 1969-04-01 | 1972-12-05 | Egyt Gyogyszervegyeszeti Gyar | Indazole-3-carboxylic amides |
| CA2281664A1 (en) | 1997-02-26 | 1998-09-03 | Robert William Wiethe | Reverse hydroxamate derivatives as metalloprotease inhibitors |
| ZA988967B (en) | 1997-10-03 | 2000-04-03 | Du Pont Pharm Co | Lactam metalloprotease inhibitors. |
| SE9704545D0 (sv) | 1997-12-05 | 1997-12-05 | Astra Pharma Prod | Novel compounds |
| SE9704546D0 (sv) | 1997-12-05 | 1997-12-05 | Astra Pharma Prod | Novel compounds |
| SE9704544D0 (sv) | 1997-12-05 | 1997-12-05 | Astra Pharma Prod | Novel compounds |
| CA2333554A1 (en) | 1998-06-17 | 1999-12-23 | Chu-Baio Xue | Cyclic hydroxamic acids as metalloproteinase inhibitors |
| US6239151B1 (en) | 1998-06-26 | 2001-05-29 | Hoffmann-La Roche Inc. | Compounds as inhibitor of tumor necrosis factor alpha release |
| UA59453C2 (uk) | 1998-08-12 | 2003-09-15 | Пфайзер Продактс Інк. | Похідні гідроксипіпеколат гідроксамової кислоти як інгібітори матричних металопротеїназ |
| US20040122011A1 (en) | 1998-12-23 | 2004-06-24 | Pharmacia Corporation | Method of using a COX-2 inhibitor and a TACE inhibitors as a combination therapy |
| US6225311B1 (en) | 1999-01-27 | 2001-05-01 | American Cyanamid Company | Acetylenic α-amino acid-based sulfonamide hydroxamic acid tace inhibitors |
| CZ20013608A3 (cs) | 1999-04-09 | 2002-05-15 | Astrazeneca Ab | Adamantanové deriváty |
| SE9901875D0 (sv) | 1999-05-25 | 1999-05-25 | Astra Pharma Prod | Novel compounds |
| SE9904505D0 (sv) | 1999-12-09 | 1999-12-09 | Astra Pharma Prod | Novel compounds |
| TWI258462B (en) | 1999-12-17 | 2006-07-21 | Astrazeneca Ab | Adamantane derivative compounds, process for preparing the same and pharmaceutical composition comprising the same |
| SE9904652D0 (sv) | 1999-12-17 | 1999-12-17 | Astra Pharma Prod | Novel Compounds |
| SE9904738D0 (sv) | 1999-12-22 | 1999-12-22 | Astra Pharma Prod | Novel compounds |
| GB0013737D0 (en) | 2000-06-07 | 2000-07-26 | Astrazeneca Ab | Novel compounds |
| AU2001280167A1 (en) | 2000-08-31 | 2002-03-13 | Wakunaga Pharmaceutical Co.,Ltd | Novel propenohydroxamic acid derivatives |
| EP1397137B1 (en) | 2001-05-25 | 2009-10-14 | Bristol-Myers Squibb Company | Hydantion derivatives as inhibitors of matrix metalloproteinases |
| WO2003016248A2 (en) | 2001-08-17 | 2003-02-27 | Bristol-Myers Squibb Company Patent Department | Bicyclic hydroxamates as inhibitors of matrix metalloproteinases and/or tnf-$g(a) converting enzyme (tace) |
| US6740649B2 (en) | 2001-09-17 | 2004-05-25 | Bristol-Myers Squibb Company | Cyclic hydroxamic acids as inhibitors of matrix metalloproteinases and/or TNF- α converting enzyme (TACE) |
| WO2003031431A1 (en) | 2001-10-09 | 2003-04-17 | Bristol-Myers Squibb Company | Cyclic sulfone derivatives as inhibitors of matrix metalloproteinases and/or tnf-$g(a) converting enzyme (tace) |
| WO2003055856A2 (en) | 2001-10-17 | 2003-07-10 | Bristol-Myers Squibb Company | BICYCLIC LACTAM DERIVATIVES AS INHIBITORS OF MATRIX METALLOPROTEINASES AND/OR TNF-α CONVERTING ENZYME (TACE) |
| US20030212056A1 (en) | 2001-11-02 | 2003-11-13 | Jingwu Duan | Beta-sulfone derivatives as inhibitors of matrix metalloproteinases and/or TNF-alpha converting enzyme (TACE) |
| PA8557501A1 (es) | 2001-11-12 | 2003-06-30 | Pfizer Prod Inc | Benzamida, heteroarilamida y amidas inversas |
| WO2003042190A1 (en) | 2001-11-12 | 2003-05-22 | Pfizer Products Inc. | N-alkyl-adamantyl derivatives as p2x7-receptor antagonists |
| SE0103836D0 (sv) | 2001-11-16 | 2001-11-16 | Astrazeneca Ab | Novel compounds |
| WO2003047515A2 (en) | 2001-11-30 | 2003-06-12 | The Government Of The United States Of America, Represented By The Secretary, Department Of Health And Human Services | P2x7 receptor antagonists |
| AU2002357312A1 (en) | 2001-12-20 | 2003-07-09 | Bristol-Myers Squibb Company | Barbituric acid derivatives as inhibitors of tnf-alpha converting enzyme (tace) and/or matrix metalloproteinases |
| JP2005517684A (ja) | 2001-12-21 | 2005-06-16 | キング ファーマシューティカルズ リサーチ アンド ディベロップメント インコーポレイテッド | チロシル誘導体及びｐ２ｘ７受容体モジュレーターとしてのそれらの使用 |
| AU2003220401A1 (en) | 2002-03-18 | 2003-10-08 | Bristol-Myers Squibb Company | Uracil derivatives as inhibitors of tnf-alpha converting enzyme (tace) and matrix metalloproteinases |
| SE0200920D0 (sv) | 2002-03-25 | 2002-03-25 | Astrazeneca Ab | Novel compounds |
| GB0216379D0 (en) | 2002-07-13 | 2002-08-21 | Astrazeneca Ab | Compounds |
| US7102008B2 (en) | 2002-08-01 | 2006-09-05 | Bristol-Myers Squibb Company | Hydantoin derivatives as inhibitors of matrix metalloproteinases and/or TNF-α converting enzyme |
| AU2003282920A1 (en) | 2002-10-04 | 2004-05-04 | Bristol-Myers Squibb Company | Hydantoin derivatives as inhibitors of matrix metalloproteinases and/or tnf-alpha converting enzyme (tace) |
| AU2003284001A1 (en) | 2002-10-07 | 2004-05-04 | Bristol-Myers Squibb Company | Triazolone and triazolethione derivatives |
| US7125870B2 (en) | 2002-11-06 | 2006-10-24 | Bristol-Myers Squibb Company | Isoxazoline derivatives as inhibitors of matrix metalloproteinases and/or TNF-α converting enzyme |
| PA8591801A1 (es) | 2002-12-31 | 2004-07-26 | Pfizer Prod Inc | Inhibidores benzamidicos del receptor p2x7. |
| BR0317844A (pt) | 2002-12-31 | 2005-12-06 | Pfizer Prod Inc | Inibidores de benzamida do receptor p2x7 |
| ITMI20030287A1 (it) * | 2003-02-18 | 2004-08-19 | Acraf | Indazolammidi dotate di attivita' analgesica metodo, per |
| SE0300480D0 (sv) | 2003-02-21 | 2003-02-21 | Astrazeneca Ab | Novel compounds |
| MXPA05012086A (es) | 2003-05-12 | 2006-02-22 | Pfizer Prod Inc | Inhibidores de benzamida del receptor p2x7. |
| GB0312609D0 (en) | 2003-06-02 | 2003-07-09 | Astrazeneca Ab | Novel compounds |
| US7132432B2 (en) | 2003-06-05 | 2006-11-07 | Bristol-Myers Squibb Company | Hydantoin derivatives as inhibitors of tumor necrosis factor-alpha converting enzyme (TACE) |
| JP2007516203A (ja) * | 2003-07-09 | 2007-06-21 | バイオリポックス エービー | 炎症の治療に有用なインドール類 |
| SE0302035D0 (sv) * | 2003-07-09 | 2003-07-09 | Biolipox Ab | New compound |
| GB0324498D0 (en) | 2003-07-21 | 2003-11-26 | Aventis Pharma Inc | Heterocyclic compounds as P2X7 ion channel blockers |
| SE0302139D0 (sv) | 2003-07-28 | 2003-07-28 | Astrazeneca Ab | Novel compounds |
| SE0302192D0 (sv) | 2003-08-08 | 2003-08-08 | Astrazeneca Ab | Novel compounds |
| WO2005019182A1 (en) | 2003-08-20 | 2005-03-03 | Bayer Healthcare Ag | Pyrazolylmethylbenzamide derivatives as p2xt-receptor antagonists |
| JP2007509180A (ja) | 2003-10-21 | 2007-04-12 | インスパイアー ファーマシューティカルズ，インコーポレイティド | 疼痛を治療するための、非ヌクレオチド組成物および方法 |
| JP2007535553A (ja) | 2004-04-29 | 2007-12-06 | アボット・ラボラトリーズ | アミノ−テトラゾール類縁体および使用方法 |
| AU2005258924A1 (en) | 2004-06-29 | 2006-01-12 | Pfizer Products Inc. | Method for preparing 5-`4-(2-hydroxy-ethyl)-3,5-dioxo-4,5-dihydro-3H-`1,2,4!-triazin-2-YK!benzamide derivatives with P2x7 inhibiting activity by reaction of the derivative unsubstituted in 4-position of the triazine with an oxiran in the presence of a lewis acid |
| JP2008504360A (ja) | 2004-06-29 | 2008-02-14 | ファイザー・プロダクツ・インク | ヒドロキシル保護された前駆体を脱保護することによる５−［４−（２−ヒドロキシ−プロピル）−３，５−ジオキソ−４，５−ジヒドロ−３ｈ−１，２，４−トリアジン−２−イル］−ベンズアミド誘導体の製造方法 |
| US7241776B2 (en) | 2004-08-02 | 2007-07-10 | Abbott Laboratories | Cyanoamidine P2X7 antagonists for the treatment of pain |
| SA05260265A (ar) | 2004-08-30 | 2005-12-03 | استرازينيكا ايه بي | مركبات جديدة |
| SE0402925D0 (sv) | 2004-11-30 | 2004-11-30 | Astrazeneca Ab | Novel Compounds |
| MY140868A (en) | 2004-12-24 | 2010-01-29 | Astrazeneca Ab | Amide derivatives |
| EP1844003A4 (en) | 2005-01-27 | 2010-09-22 | Astrazeneca Ab | NEW BIAROMATIC COMPOUNDS AS INHIBITORS OF THE P2X7 RECEPTOR |
| US20060211739A1 (en) | 2005-02-08 | 2006-09-21 | Arturo Perez-Medrano | Use of selective P2X7 receptor antagonists |
| US7402596B2 (en) | 2005-03-24 | 2008-07-22 | Renovis, Inc. | Bicycloheteroaryl compounds as P2X7 modulators and uses thereof |
| WO2006110516A1 (en) | 2005-04-11 | 2006-10-19 | Abbott Laboratories | Acylhydrazide p2x7 antagonists and uses thereof |
| CA2607541A1 (en) | 2005-05-05 | 2006-12-28 | Medicure International Inc. | Inhibition of atp-mediated, p2x7 dependent pathways by pyridoxal-5-phosphaste and vitamin b6 related compounds |
| WO2007016597A2 (en) | 2005-07-29 | 2007-02-08 | The Regents Of The University Of California | Targeting tnf-alpha converting enzyme (tace)-dependent growth factor shedding in cancer therapy |
| WO2007025366A1 (en) | 2005-08-29 | 2007-03-08 | Irma Bernatchez-Lemaire | Use of histogranin and histogranin-like compounds as inhibitors of p2x7 receptor function and as anti-arthritic agents |
| WO2007028022A2 (en) | 2005-09-01 | 2007-03-08 | Renovis, Inc. | Novel compounds as p2x7 modulators and uses thereof |
| WO2007056046A1 (en) | 2005-11-07 | 2007-05-18 | Abbott Laboratories | P2x7 receptor antagonists and methods of use |
| CN101304975A (zh) | 2005-11-09 | 2008-11-12 | 艾博特公司 | P2x7受体拮抗剂及其用途 |
| WO2007109154A2 (en) | 2006-03-16 | 2007-09-27 | Renovis, Inc. | Bicycloheteroaryl compounds as p2x7 modulators and uses thereof |
| TWI464148B (zh) | 2006-03-16 | 2014-12-11 | Evotec Us Inc | 作為ｐ２ｘ7調節劑之雙環雜芳基化合物與其用途 |
| WO2007109182A2 (en) | 2006-03-16 | 2007-09-27 | Renovis, Inc. | Bicycloheteroaryl compounds as p2x7 modulators and uses thereof |
| US8546579B2 (en) | 2006-03-16 | 2013-10-01 | Evotec (Us) Inc. | Bicycloheteroaryl compounds as P2X7 modulators and uses thereof |
| US20100184802A1 (en) | 2006-03-16 | 2010-07-22 | Kelly Michael G | Bicycloheteroaryl Compounds as P2X7 Modulators and Uses Thereof |
| WO2007109160A2 (en) | 2006-03-16 | 2007-09-27 | Renovis, Inc. | Bicycloheteroaryl compounds as p2x7 modulators and uses thereof |
| GB0611154D0 (en) | 2006-06-06 | 2006-07-19 | Glaxo Group Ltd | Novel receptor antagonists and their methods of use |
| JP2009539795A (ja) | 2006-06-06 | 2009-11-19 | グラクソ グループ リミテッド | 疼痛、炎症および神経変性の治療のためのｐ２ｘ７アンタゴニストとしてのｎ−（フェニルメチル）−２−（１ｈ−ピラゾール−４−イル）アセトアミド誘導体 |
| US20080076924A1 (en) | 2006-06-30 | 2008-03-27 | Patrick Betschmann | Piperazines as P2X7 antagonists |
| US7718693B2 (en) | 2006-07-06 | 2010-05-18 | Glaxo Group Limited | Receptor antagonists and their methods of use |
| BRPI0812594A2 (pt) * | 2007-08-10 | 2015-06-23 | Lundbeck & Co As H | Composto ou sal ou hidrato do mesmo, composição farmacêutica, métodos para modulação da atividade de um receptor p2x7, para tratamento de uma condição responsiva á modulação do receptor p2x7 em um paciente, para inibição de morte de células gangliônicas retinais em um paciente, para determinação da presença ou ausência de receptor p2x7 em uma amostra, preparação farmacêutica acondicionada, e, uso de um composto ou sal ou hidrato do mesmo. |
| US8232290B2 (en) * | 2008-03-25 | 2012-07-31 | Affectis Pharmaceuticals Ag | P2X7R antagonists and their use |
-
2010
- 2010-03-11 EP EP10156190A patent/EP2243772B1/en not_active Not-in-force
- 2010-03-11 CA CA2758474A patent/CA2758474A1/en not_active Abandoned
- 2010-03-11 WO PCT/EP2010/053097 patent/WO2010118921A1/en not_active Ceased
- 2010-03-11 PT PT10156190T patent/PT2243772E/pt unknown
- 2010-03-11 CN CN2010800166929A patent/CN102395562A/zh active Pending
- 2010-03-11 AU AU2010237302A patent/AU2010237302A1/en not_active Abandoned
- 2010-03-11 KR KR1020117026988A patent/KR20120006547A/ko not_active Withdrawn
- 2010-03-11 SG SG2011075140A patent/SG175232A1/en unknown
- 2010-03-11 JP JP2012505103A patent/JP2012523440A/ja active Pending
- 2010-03-11 AT AT10156190T patent/ATE541832T1/de active
- 2010-03-11 PL PL10156190T patent/PL2243772T3/pl unknown
- 2010-03-11 ES ES10156190T patent/ES2380908T3/es active Active
- 2010-03-11 BR BRPI1014902A patent/BRPI1014902A2/pt not_active IP Right Cessation
- 2010-03-11 EA EA201101479A patent/EA201101479A1/ru unknown
- 2010-03-11 MX MX2011010810A patent/MX2011010810A/es active IP Right Grant
- 2010-03-11 SI SI201030020T patent/SI2243772T1/sl unknown
- 2010-03-11 DK DK10156190.0T patent/DK2243772T3/da active
- 2010-04-12 US US12/758,557 patent/US7919503B2/en not_active Expired - Fee Related
-
2011
- 2011-02-25 US US13/035,614 patent/US8268861B2/en not_active Expired - Fee Related
- 2011-09-27 IL IL215444A patent/IL215444A0/en unknown
- 2011-11-11 ZA ZA2011/08305A patent/ZA201108305B/en unknown
-
2012
- 2012-03-27 HR HR20120271T patent/HRP20120271T1/hr unknown
- 2012-04-04 CY CY20121100340T patent/CY1112758T1/el unknown
- 2012-04-25 SM SM201200017T patent/SMT201200017B/it unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2012523440A5 (enExample) | ||
| CA2758474A1 (en) | Novel p2x7r antagonists and their use | |
| CA2395717C (en) | Fused imidazolium derivatives | |
| JP6505023B2 (ja) | Ｃｎｓおよび他の障害を治療するための、ｐｄｅ４アイソザイムの阻害薬としてのアザベンゾイミダゾール化合物 | |
| ME01488B (me) | Derivati oksadiazola i njihovo korišćenje kao potencijatora metabotropnih glutamatnih receptora-842 | |
| JP6592510B2 (ja) | Ｐ２ｘ７調節因子 | |
| MY156747A (en) | Isoxazolo-pyridine derivatives | |
| JP2017508733A5 (enExample) | ||
| RU2012103487A (ru) | Ингибирующие jak соединения на основе пиразолопиримидина и способы | |
| JP2005516067A5 (enExample) | ||
| TNSN07164A1 (en) | Quinuclidine derivatives and their use as muscarinic m3 receptor antagonists | |
| HRP20180973T1 (hr) | Supstituirani tiazolski ili oksazolski antagonisti p2x7 receptora | |
| MX2010002576A (es) | Compuestos que contienen guanidina, utiles como antagonistas de los receptores muscarinicos. | |
| JP2016540749A5 (enExample) | ||
| NZ602395A (en) | Substituted fused imidazole derivatives, pharmaceutical compositions, and methods of use thereof | |
| JP2008543860A5 (enExample) | ||
| MX2009013885A (es) | Derivados de quinolina fusionados utiles como moduladores de acido gamma-aminobutirico. | |
| JO2676B1 (en) | Derivatives of second-aza-spiro- (5,4) -dikan and their use as antihistamines | |
| MX2009008527A (es) | Compuestos de amonio cuaternario y difenilmetilo utiles como antagonistas del receptor muscarinico. | |
| JP2010522731A (ja) | Ｃｒｔｈ２受容体リガンドとしてのキノリン誘導体 | |
| JO2527B1 (en) | Derivatives of second-aza-Spiro- (5,5) -andecan and their use as antihistamines | |
| JP2013514974A5 (enExample) | ||
| JP2013525490A5 (enExample) | ||
| HRP20140881T1 (hr) | Benzensulfonamidni spojevi, postupak njihove sinteze i njihova upotreba u medicini | |
| HRP20151003T1 (hr) | Novi spojevi kao ligandi receptora histamina h3 |